The case in front of me: early satiety · oral semaglutide.
I want to know whether this is a real physical effect or an artefact of how it is measured.
What prompted the question is an inconsistency between two sources I otherwise trust.
Is the standard explanation correct, and if so, what is the evidence for it?
Start with which symptom predominates, because the management diverges sharply even though the mechanism does not.
Symptom prevalence in trials, broadly: nausea a quarter to a half, diarrhoea and constipation each roughly ten to twenty per cent, vomiting rather less, with all rates rising with dose.
| Event | Active arm | Placebo arm | Timing |
|---|---|---|---|
| Nausea | 40–45 % | 15–20 % | Peaks 1–2 wk after each step |
| Vomiting | 15–25 % | 5–8 % | Follows nausea |
| Diarrhoea | 20–30 % | 10–15 % | Early, variable |
| Constipation | 20–25 % | 8–12 % | Later onset, persistent |
| Discontinuation for GI events | 4–7 % | 1–2 % | Mostly during escalation |
Ranges span agents and doses; read the specific prescribing information for a specific figure.
Concretely, symptoms that appear for the first time at a stable dose after months are not the ordinary pattern and warrant looking for another explanation.
Nothing here is medical advice.
New symptoms at a stable dose after months need a different explanation.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsThis is the group of effects that drives almost all discontinuation in the trial programmes.
Reflux occurs because a slower-emptying stomach retains volume for longer against a lower oesophageal sphincter that has not changed. Smaller meals and not lying down within a few hours are the direct responses.
Discontinuation for gastrointestinal effects in the trials runs in the low single-figure percentages, which means the great majority of people who experience these effects continue.
Most people who report these effects continue. The discontinuation rate is low.
Diarrhoea and constipation both occur, which surprises people until they consider how many mechanisms are involved.
Fat is the macronutrient that slows emptying most on its own, so a high-fat meal on top of pharmacologically delayed emptying is the combination that produces the worst episodes.
It helps to be literal here: gastric emptying of a solid meal can be delayed substantially at initiation. The effect is largest early and attenuates over weeks for the long-acting agents, which is the mechanistic basis for the titration schedule.
Trial-reported incidence and discontinuation rates for gastrointestinal effects are published per agent and per dose and are the appropriate figures to quote.
Slow the titration first. It is the intervention with the best evidence and the lowest cost.
edited 29 Jul 2026 by gradient_slope — added the citation requested in comments
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.